z-logo
Premium
Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3
Author(s) -
Selvendiran Karuppaiyah,
Bratasz Anna,
Kuppusamy M. Lakshmi,
Tazi Mia F.,
Rivera Brian K.,
Kuppusamy Periannan
Publication year - 2009
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.24601
Subject(s) - stat3 , ovarian cancer , cisplatin , cancer research , stat protein , apoptosis , hypoxia (environmental) , biology , cancer cell , activator (genetics) , chemotherapy , cell culture , cancer , medicine , chemistry , receptor , biochemistry , organic chemistry , genetics , oxygen
Signal transducer and activator of transcription 3 (STAT3) is activated in a variety of human cancers, including ovarian cancer. The molecular mechanism by which the STAT3 is activated in cancer cells is poorly understood. We observed that human ovarian xenograft tumors (A2780) in mice were severely hypoxic (pO 2 ∼ 2 mmHg). We further observed that hypoxic exposure significantly increased the phosphorylation of STAT3 (pSTAT3) at the Tyr705 residue in A2780 cell line. The pSTAT3 (Tyr705) level was highly dependent on cellular oxygenation levels, with a significant increase at <2% O 2 , and without any change in the pSTAT3 (Ser727) or total STAT3 levels. The pSTAT3 (Tyr705) elevation following hypoxic exposure could be reversed within 12 hr after returning the cells to normoxia. The increased level of pSTAT3 was partly mediated by increased levels of reactive oxygen species generation in the hypoxic cancer cells. Conventional chemotherapeutic drugs cisplatin and taxol were far less effective in eliminating the hypoxic ovarian cancer cells suggesting a role for pSTAT3 in cellular resistance to chemotherapy. Inhibition of STAT3 by AG490 followed by treatment with cisplatin or taxol resulted in a significant increase in apoptosis suggesting that hypoxia‐induced STAT3 activation is responsible for chemoresistance. The results have important clinical implications for the treatment of hypoxic ovarian tumors using STAT3‐specific inhibitors. © 2009 UICC

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here